Pharmafile Logo
Pharmafocus logo
Advanced Search
cancer_cells

Roche’s cholesterol-lowering drug candidate shows promise in fighting prostate cancer

April 15, 2016
Medical Communications, Research and Development RO 48-9071, Roche, cholesterol, drug, missouri, oncology, university

Researchers from the University of Missouri have found that a compound developed by Roche Pharmaceuticals for the treatment of high …

News
clinical_trial_4

Synta Pharmaceuticals announces merger with Madrigal

April 15, 2016
Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Phase II, Synta, madrigal, merger

Synta Pharmaceuticals (NASDAQ: SNTA) has announced a definitive merger agreement with Madrigal Pharmaceuticals under which the newly-formed company will focus …

News
mr058666-web

Merck appoints Maya Martinez-Davis as global head of oncology

April 14, 2016
Medical Communications Merck, maya martinez-davis, oncology

Merck has announced the appointment of Maya Martinez-Davis as the new global head of oncology at the German-based company. In …

Appointment

Merck says US FDA to review its Keytruda for head & neck cancer

April 14, 2016
Research and Development, Sales and Marketing Cancer Immunotherapy, Merck & Co, US FDA, keytruda

The US Food and Drug Administration has accepted Merck & Co’s (NYSE: MRK) supplemental biologics license application (sBLA) for its immunotherapy cancer …

News
aedes_aegypti_mosquito

Zika causes microcephaly and other birth defects, says CDC

April 14, 2016
Medical Communications, Research and Development CDC, Zika, Zika virus, birth defects, microcephaly

The US Centers for Disease Control and Prevention has concluded that the Zika virus is a cause of microcephaly and …

News
merck-sharp--dohme-corp

Merck says its Zepatier showed better efficacy and safety compared with competition in Phase III trials

April 14, 2016
Research and Development, Sales and Marketing Gilead, HCV, Merck & Co, Zepatier

US pharma giant Merck (NYSE: MRK) on Thursday said late-stage trials for its Zepatier (elbasvir and grazoprevir) to treat chronic …

News
abbvie_0

AbbVie announces positive Phase III results in hepatitis C drug

April 14, 2016
Manufacturing and Production, Research and Development AbbVie, hepatitis, phase III

AbbVie (NYSE: ABBV) has announced positive results from their Phase III evaluating the combination of Viekirax and Exviera, with or …

News

NICE issues new guidance on the safer use of controlled drugs

April 13, 2016
Medical Communications NICE, controlled drugs, guidance

The National Institute for Health and Care Excellence (NICE) has issued guidance bringing together legislation and existing advice on the …

News
sanofi_hq__boetie_hall

Sanofi reinforces collaboration with Stevenage Bioscience Catalyst with partnering office

April 13, 2016
Manufacturing and Production, Research and Development, Sales and Marketing Sanofi, Stevenage Bioscience Catalyst, academia, industry, partnership, pharma, stevenage

Sanofi has reinforced its collaboration with Stevenage Bioscience Catalyst with the opening of a new partnering office. This office will …

News
opdivo_1

Bristol-Myers Squibb cancer immunotherapy Opdivo approved in EU

April 13, 2016
Manufacturing and Production, Research and Development, Sales and Marketing Bristol-Myers Squibb, Cancer, EU, NICE, approval, immunotherapy, opdivo

Bristol-Myers Squibb has announced that its potentially life-extending cancer immunotherapy, Opdivo (nivolumab), has been approved by the European Commission to …

News
fda_logo-web

US FDA committee recommends against fast-track approval of Clovis’ cancer drug, asks for more data

April 13, 2016
Medical Communications, Research and Development

Shares in Clovis Oncology Inc (Nasdaq: CLVS) closed down 5.4% Tuesday after the US Food and Drug Administration advisory committee recommended …

News
zika_purdue

Structure of Zika virus revealed in new study

April 13, 2016
Research and Development NIH, Purdue, Zika, glycoprotein, structure

Researchers have examined the structure of the Zika virus in a new study and found that is broadly similar to …

News
msd

FDA accepts biologics license application for MSD’s allergy immunotherapy drug

April 13, 2016
Research and Development, Sales and Marketing MSD, Merck, allergy, dust mite, house, immunotherapy, mk-8237

MSD (NYSE: MRK) has announced that the US Food and Drug Administration has accepted for review the biologics license application …

News
birdlr

Boehringer Ingelheim’s Giotrif significantly lowers lung cancer progression in Phase II trials

April 13, 2016
Research and Development AstraZeneca, Boehringer Ingelheim, Iressa, giotrif, lung cancer

German drugmaker Boehringer Ingelheim on Wednesday said a mid-stage study has shown its cancer drug Giotrif (afatinib) reduced the risk …

News
stocks2

Valeant bondholders issue notice to default

April 13, 2016
Research and Development, Sales and Marketing Valeant, bondholders, default, fears, possibility

Valeant (NYSE: VRX) has issued a statement detailing plans from some of its bondholders to call a default because of …

News
cancer

Focus: Ovarian cancer and the case of elusive cure

April 12, 2016
Research and Development J&J, JJ, Pfizer, drug trials, ovarian cancer

Each year, more than 21,000 women in the US are diagnosed with ovarian cancer, according to research and more than …

Feature
chemo-web

EUSA Pharma acquires global rights to oncology support drug

April 12, 2016
Manufacturing and Production, Research and Development, Sales and Marketing Eusa Pharma, acroral, acroral tab, global rights, oncology

EUSA Pharma has announced the acquisition of global rights to oncology support care product, Arcoral Tab, from Arcoral Pharma.

News
regeneron

Regeneron agrees six-year $75 million upfront licencing deal with Intellia for gene technology

April 12, 2016
Manufacturing and Production, Research and Development, Sales and Marketing IPO, Intellia Therapeutics, Licencing, Regeneron Pharmaceuticals, crispr, deal, gene editing, genetics

Regeneron Pharmaceuticals Inc (Nasdaq: REGN) on Tuesday said it has signed a six-year licencing deal with biotech firm Intellia Therapeutics …

News
dollars_medicines

KaloBios announces new affordable pricing model, refuses to engage in “price gouging”

April 12, 2016
Manufacturing and Production, Sales and Marketing CEO, Drug pricing, KaloBios, Martin Shkreli, Shkreli, affordable, price gouging, price model, responsible

Price gouging has become synonymous with drug costs in the US, with the infamous Martin Shkreli and troubled Valeant becoming …

News
astrazeneca_sign_sky

Clinical studies point to consistent efficacy in AstraZeneca’s treatment for drug-resistance bacteria

April 12, 2016
Manufacturing and Production, Research and Development AstraZeneca, avibactam, ceftazidime, gram resistant

AstraZeneca has presented results from a series of trials which show the consistent efficacy of investigational antibiotic, ceftazidime-avibactam (CAZ-AVI) in …

News
The Gateway to Local Adoption Series

Latest content

Ofichem brings all brands under single trading name

April 23, 2026

Carvolix strengthens its Board of Directors, advisory board and governance structure

April 23, 2026

Under-Secretary of State for Health Innovation and Safety visits new building on University of Huddersfield’s NHIC

April 22, 2026

Incyclix Bio announces new additions to the Board

April 22, 2026

Remedy Plan Therapeutics Appoints Jotin Marango as CFO and CBO

April 21, 2026